Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Artemether-Lumefantrine · Coartem

Small molecule · Acts on Plasmodium falciparum · developed by Novartis Pharmaceuticals

Approved FDA
1 Registered trials

What is Artemether-Lumefantrine?

Artemether-lumefantrine is a fixed-dose combination antimalarial containing artemether and lumefantrine in a 1:6 ratio.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Coartem
Drug type
Small molecule
Targets
Plasmodium falciparum
Mechanism
Acts on Plasmodium falciparum
Therapy area
Infectious disease
Developer
Novartis Pharmaceuticals Corporation
In trials of
IBO
FDA status
Approved as Coartem, NDA022268 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05340153 Phase 4 Malaria Unknown IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malaria

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.